A free, virtual Forum focused on the growing Digital Health industry in the Baltimore/Washington region and beyond, presented by EAGB & BHI.
The Economic Alliance of Greater Baltimore (www.greaterbaltimore.org) and BioHealth Innovation (www.biohealthinnovation.org) have partnered to host a Forum focused on the growing Digital Health industry in the Baltimore/Washington region and beyond. The Forum is free and will be held virtually on March 25, from1 – 3:00 pm. There is no fee and all are welcomed, but you must register in order to receive the link to the event.
The Digital Health Forum features two panel discussions and a moderated conversation. Brief welcome comments by Rich Bendis and Michele Whelley, CEO of BHI and EAGB, respectively, will open the Forum.
PANEL ONE: The Role of Academia in Digital Health
PANEL TWO: Digital Health in Healthcare
CLOSING CONVERSATION: International Collaboration in Digital Health
Are you a biohealth company with innovative technology seeking funds to advance your commercialization activities? Do not miss a unique opportunity to discuss your innovation research and commercialization plans directly with Program Officers from NSF, NIH and its individual institutes (NCI, NIA, NIAID, NIDA, NHLBI) and the University of Maryland MIPS. Learn how to write compelling Research Aims and Commercialization Plans, current areas of focus for nondilutive funding resources, additional government resources, and best industry strategies to support your firm’s growth. Confirmed speakers/partnering meeting participants include:
Henry Ahn – Program Director, National Science Foundation (NSF)
Stephanie Davis, PhD – Small Business Program Coordinator, NIH Nat’l Heart Lung & Blood Inst. (NHLBI)
Sharon Disque, Economic Development Manager, City of Gaithersburg, Maryland
Stephanie Fertig, HHS Small Business Program Lead, National Institutes of Health (NIH)
Jonathan Franca-Koh, PhD – Program Director, SBIR Development Center, National Cancer Inst (NCI).
Armineh Ghazarian – Senior Program Analyst, NIH National Institute on Aging (NIA)
Colleen Gibney, SBIR Deputy Project Manager, US Army Medical Research & Dev. Command (USAMRDC)
Luis Gutierrez – Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
Todd Haim, PhD – Chief, Office of Small Business Research, NIH National Institute on Aging (NIA)
Elena Koustova, PhD, MBA – Director, Office of Translational Initiatives and Program Innovations (OTIPI), NIDA SBIR/STTR Coordinator, NIH National Institute of Drug Abuse (NIDA) Office of Director
Ashwin Kulkarni, COO, miRecule; Associate, BioHealth Innovation, Inc. (BHI)
Natalia Kruchinin, PhD – SBIR/STTR Program Coordinator, RTSP, DEA, National Institute of Allergy and Infectious Diseases
Carla Merritt, Senior Business Development Representative, Maryland Department of Commerce
JR Myers, SBIR Project Manager, US Army Medical Research & Development Command (USAMRDC)
Mike Minicozzi, PhD, Senior Program Officer, DAIT, National Institute of Allergy and Infectious Diseases
Alastair Monk – Program Director, National Science Foundation (NSF)
Deepa Narayanan – Program Director and Team Lead, NIH National Cancer Institute SBIR Development Center (NCI)
Rini Pek, PhD – Senior Analyst, BioHealth Innovation, Inc. (BHI)
Erik Pierstorff – Program Director, National Science Foundation (NSF)
Victor Prikhodko – Senior Business Dev. Mgr., SBIR/STTR NIH National Inst. of Drug Abuse (NIDA)
Monique Pond, PhD – Program Director, SBIR Development Center, National Cancer Institute
Reema Railkar, PhD – Program Manager, SBIR Development Center, National Cancer Institute
Saroj Regmi, PhD – Health Science Administrator, Office of Small Business Research, NIH National Institute on Aging
Andrea Renner – Technical Assistance Advocate, US Army Medical Research & Dev Command (USAMRDC)
Ethel Rubin, PhD – Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
Ben Schrag,PhD – Program Director, National Science Foundation (NSF)
John Sullivan – Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
Onur Unal, Manager, Life Sciences Projects, Maryland Industrial Partnerships (MIPS), Maryland Technology Enterprise Institute (MTech), University of Maryland
Register (no fee) today!www.tinyurl.com/2021SBIRQuestions: BHI@BioHealthInnovation.orgNOTE: Different institutes are available to meet at different times during the March 17-19th period. You will be able to request meetings once you have registered and received the partnering log-in.
Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join BioTalk to discuss RNA Disease Diagnostics, UM Ventures, and the commercialization of new medical technologies
Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs on one of the following dates. Pre-registration is required; Sign up here tinyurl.com/EIRfeedback
They are joining a program that plans to expand in the D.C. region with a new leader.
Image: Melinda Gates’ incubation and investment firm, Pivotal Ventures, is funding a new initiative at the University of Maryland and George Mason University to draw more women to their tech degree programs. THE NEW YORK TIMES/KYLE JOHNSON
Montgomery College and the Universities at Shady Grove (USG), in conjunction with the University of Maryland, Baltimore County (UMBC), have completed two intensive pilot training programs designed to create a skilled talent pipeline to support the life sciences sector in Montgomery County. The four-week “Bio Boot Camp” program—a public-private effort announced in November 2020—was created to help kickstart recovery from the COVID-19 health crisis.
COLUMBIA, Md. (March 8, 2021)—TEDCO, Maryland’s economic engine for technology companies, announced today its Seed Fund invested $400,000 in two technology start-ups. TEDCO’s Seed Fund invests in early-stage, technology and life sciences companies and includes gap financing.
The federal lab system is an enormous $50 billion-plus enterprise of internal research and development taking place in federal facilities across the United States. As other governments around the world, including China, pour billions of dollars into government labs and research parks focused on advanced technologies, it is imperative that we use all aspects of country’s own innovation ecosystem in the most creative ways possible, including our federal labs.
The National Institutes of Health funds what it calls extramural research in a wide variety of fields. Our guest has for many years worked to ensure that small enterprises got their share of the grants. Now she’s the recipient of a Tibbets Award from the Small Business Administration for advancing the Small Business Technology Transfer and Small Business Innovation Research programs. For more, the director of the Office of Clinical Policy and Programs at the FDA., Dr. Jodi Black, joined Federal Drive with Tom Temin.
SARS-CoV-2 vaccinations are accelerating across the U.S. with approximately 66 million first doses having been administered as of February 25th, representing 13.6% of the country, according to NPR. The vaccination effort received another boost with the Food and Drug Administration’s recent Emergency Use Authorization (EUA) of Johnson & Johnson’s (J&J) single-dose vaccine.
GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH) are currently working on two vaccine projects. The first is to prevent Group A Streptococcus infections, commonly known as Strep Throat, which is a major reason for antibiotic prescriptions and cause of immune-mediated diseases.
The second project GSK is working is a vaccine to prevent infections caused by Salmonella enterica, which cause Invasive nontyphoidal salmonellosis (iNTS) disease and typhoid fever, major causes of death among children and significant health challenges primarily in sub-Saharan African countries.
As the U.S. makes headway in its coronavirus vaccination campaign, Emergent BioSolutions CEO Bob Kramer appeared on CNBC Wednesday to explain his company’s role in manufacturing doses.
The Gaithersburg, Maryland-based contractor last year landed a multi-year deal to be the domestic producer of the Covid-19 vaccine from Johnson & Johnson, whose single-dose shot was cleared for use in the U.S. over the weekend. It also has a multi-year contract production contract for a vaccine developed by a British-Swedish biopharmaceutical company, AstraZeneca.
HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.
QIAsphere sets new standards for syndromic testing digital health, providing users with remote visibility of their testing routine. It can monitor a nearly unlimited number of instruments, providing visibility of testing routine across different hospitals or satellite labs. The continuous connectivity to QIAGEN service reduces systems downtime and enabling fast and accurate syndromic testing. Digital diagnostics and remote analytics will be crucial to bring syndromic testing closer to patients in the coming years.
Washington, D.C.-based Children’s National Hospital, Virginia Tech and Johnson & Johnson Innovation have partnered to launch a new healthcare technology and research innovation campus, according to a March 1 news release.
The Children’s National Research & Innovation Campus will feature research into new pediatric medical treatments and technologies as well as a life sciences incubator for about 50 startups across the pharmaceutical, medical device, consumer and health tech sectors.
The entrepreneurs behind an exited Baltimore biotech company are creating a new center for immigration law in the city.
A $5 million gift from Marco and Debbie Chacón to the University of Maryland Francis King Carey School of Law will help to establish the Baltimore-based school’s new Chacón Center for Immigrant Justice.
The couple founded Paragon Bioservices, the contract manufacturing and development company that was acquired by Catalent in 2019 for $1.2 billion. Marco Chacón served as CEO and Debbie Chacón served as VP when the company moved to the University of Maryland BioPark in 2009. Now known as Paragon Gene Therapy, it still has a base at the BioPark, and Marco Chacón founded Irazú Bio, which is also based in the BioPark.
Image: Marco and Debbie Chacón founded Paragon Bioservices. (Photo courtesy of University of Maryland School of Law)
All eyes are on the global rollout of COVID-19 vaccines. Achieving the broad uptake needed to reach population immunity and curb the virus’s spread will require an unprecedented effort among health workers, scientists and stakeholders at every step of the supply chain.
During this 90 min event, experts from organizations central to vaccine development and delivery, regulatory oversight and quality assurance will discuss over the course of two high-level panels what’s needed for the global COVID-19 vaccination campaign, how to build public trust in the quality and effectiveness of vaccines, and how these investments can build better systems for the future.
BALTIMORE (WJZ) — As students and staff return to the classroom, state leaders are working to get every teacher vaccinated. Now, there’s a way to track the progress.
Johns Hopkins University is launching its teacher vaccination tracker.
Image: https://baltimore.cbslocal.com – From Video
Despite recent challenges, venture capital firms are still seeking out investment opportunities across the country. Since our last analysis of most active VCs in October 2020, we’ve seen shake-ups across 9 states. Our graphic maps out the most active VC investor in every US state.
Although startups based in California, New York, and Massachusetts have traditionally accounted for the majority of VC tech investment in the US, VCs are spurring other hotbeds of innovation across the country.
